Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,443.15% | 33.31% | -329.24% | 238.34% | 458.18% |
| Total Depreciation and Amortization | -31.50% | -39.81% | -16.94% | -14.09% | -27.86% |
| Total Amortization of Deferred Charges | 3.57% | 7.41% | -80.60% | -83.23% | -81.82% |
| Total Other Non-Cash Items | 480.41% | -4.98% | 448.35% | -108.05% | -191.93% |
| Change in Net Operating Assets | 22.25% | 97.10% | 218.51% | -690.24% | 171.81% |
| Cash from Operations | 26.51% | 48.07% | 455.71% | -2,441.34% | 2,251.85% |
| Capital Expenditure | -183.33% | -- | 94.83% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -1,116.95% | -- | -- |
| Cash from Investing | -111.72% | -- | -8,773.53% | -53.33% | 183.33% |
| Total Debt Issued | -2,147.29% | 209.87% | -93.54% | 33,322.22% | -- |
| Total Debt Repaid | 0.00% | 0.00% | 97.04% | -190.63% | -119.34% |
| Issuance of Common Stock | -- | -- | 338.92% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -510.00% | -378.95% | -- | -- |
| Cash from Financing | -126.92% | 152.03% | 1,116.57% | 711.13% | -2,090.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -998.28% | 1,545.10% | 5,094.72% | -1,063.20% | 166.67% |